174 related articles for article (PubMed ID: 28471205)
1. [Everolimus in Daily Clinical Practice Focusing to Oral Mucosa Damage Issues - Single Oncology Centre Experience within the Course of the Year 2016].
Vokurka S; Votavová M; Arnetová V; Korunková H; Svoboda T; Kulhánková J; Kališová K; Matějka VM; Fiala O; Fínek J
Klin Onkol; 2017; 30(Supplementum1):195-197. PubMed ID: 28471205
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE).
Schmidt M; Lübbe K; Decker T; Thill M; Bauer L; Müller V; Link T; Furlanetto J; Reinisch M; Mundhenke C; Hoffmann O; Zahn MO; Müller L; Denkert C; van Mackelenbergh M; Fasching PA; Burchardi N; Nekljudova V; Loibl S
ESMO Open; 2022 Dec; 7(6):100601. PubMed ID: 36356410
[TBL] [Abstract][Full Text] [Related]
4. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Lolli C; Gallà V; Schepisi G; Barone D; Burgio SL; Maugeri A; Vertogen B; Amadori D; De Giorgi U
Oncologist; 2017 Jul; 22(7):784-e74. PubMed ID: 28546463
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiotherapy - Current Indications.
Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
[TBL] [Abstract][Full Text] [Related]
7. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
[TBL] [Abstract][Full Text] [Related]
8. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.
Sonis S; Andreotta PW; Lyng G
Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917
[TBL] [Abstract][Full Text] [Related]
9. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.
Nicolatou-Galitis O; Nikolaidi A; Athanassiadis I; Papadopoulou E; Sonis S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Aug; 116(2):e110-6. PubMed ID: 23643584
[TBL] [Abstract][Full Text] [Related]
10. Stomatitis in mTOR inhibitors treatment and other targeted cancer therapy, possibilities of infl uencing it, and the use of local corticotherapy.
Vokurka S; Kozáková Š; Jánská V; Černá A; Liška J
Klin Onkol; 2020; 33(6):436-439. PubMed ID: 33685192
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Stomatitis: Using Dexamethasone-Based Mouthwash to Inhibit Everolimus-Related Stomatitis.
Saigal B; Guerra L
Clin J Oncol Nurs; 2018 Apr; 22(2):211-217. PubMed ID: 29547614
[TBL] [Abstract][Full Text] [Related]
12. Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity.
Žarnayová L; Kolek V; Bouchal J; Ehrmann J
Klin Onkol; 2018; 31(6):457-460. PubMed ID: 31035769
[TBL] [Abstract][Full Text] [Related]
13. Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
Niikura N; Nakatukasa K; Amemiya T; Watanabe KI; Hata H; Kikawa Y; Taniike N; Yamanaka T; Mitsunaga S; Nakagami K; Adachi M; Kondo N; Shibuya Y; Hayashi N; Naito M; Kashiwabara K; Yamashita T; Umeda M; Mukai H; Ota Y
Oncologist; 2020 Feb; 25(2):e223-e230. PubMed ID: 32043762
[TBL] [Abstract][Full Text] [Related]
14. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M; Fabi A; Moscetti L; Cazzaniga ME; Petrucelli L; Forcignanò R; Lupo LI; De Matteis E; Chiuri VE; Cairo G; Febbraro A; Giordano G; Giampaglia M; Bilancia D; La Verde N; Maiello E; Morritti M; Giotta F; Lorusso V; Latorre A; Scavelli C; Romito S; Cusmai A; Palmiotti G; Surico G
Breast Cancer Res Treat; 2017 Jun; 163(3):587-594. PubMed ID: 28353061
[TBL] [Abstract][Full Text] [Related]
15. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
16. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
Divers J; O'Shaughnessy J
Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
[TBL] [Abstract][Full Text] [Related]
17. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
[TBL] [Abstract][Full Text] [Related]
18. Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma.
Park K; Baek Y; Lee JL
Anticancer Res; 2019 Jul; 39(7):3937-3944. PubMed ID: 31262924
[TBL] [Abstract][Full Text] [Related]
19. [Controversy in the Postoperative Treatment of Low-grade Gliomas].
Kazda T; Lakomý R; Poprach A; Pospíšil P; Jančálek R; Šlampa P
Klin Onkol; 2017; 30(5):337-342. PubMed ID: 29031035
[TBL] [Abstract][Full Text] [Related]
20. [The Role of Chemotherapy in the Treatment of Low-grade Gliomas].
Lakomý R; Kazda T; Poprach A; Pospíšil P; Jančálek R; Šlampa P
Klin Onkol; 2017; 30(5):343-348. PubMed ID: 29031036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
